articleThe Lancet Diabetes & EndocrinologyFeb 4, 2022Closed access

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Toranomon Hospital · Novo Nordisk (Denmark) · +6 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

296
total citations
FWCI
35.76
Percentile
100%
References
28
Citations per year

Authors

9

Topics & keywords

Keywords
  • Medicine
  • Semaglutide
  • Overweight
  • Type 2 diabetes
  • Double blind
  • Placebo
  • Obesity
  • Population
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding